Talquetamab (Anti-CD3 & GPRC5D)

Synonyms: JNJ-64407564

Catalog No.A4026 Purity:≥99%

Talquetamab is a bispecific humanized monoclonal antibody targeting human CD3 on T cells and the multiple myeloma-associated antigen G protein-coupled receptor family C group 5 member D (GPRC5D) on tumor cells. It redirects T cells to bind and attack GPRC5D-expressing tumor cells, inducing a potent cytotoxic T-lymphocyte (CTL) response. Talquetamab is approved by the U.S. Food and Drug Administration (FDA) for patients with relapsed/refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody. MW: 144.6 KD.

Purity & Quality Control

≥99

Choose Selective CD markers Inhibitors

Name	Citation	CD38	CD45	CD39	CD88	CD73	Others
RBN013209	0	++
MK-0159	0	+++
CD38 inhibitor 1 (compound 78c)	5	+++
AB680	0					++++
NQ301	1		+				TXA2 receptor
SodiuM Metatungstate	3			++
PMX-53				✔
LY-3475070					✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description	Talquetamab is a bispecific humanized monoclonal antibody targeting human CD3 on T cells and the multiple myeloma-associated antigen G protein-coupled receptor family C group 5 member D (GPRC5D) on tumor cells. It redirects T cells to bind and attack GPRC5D-expressing tumor cells, inducing a potent cytotoxic T-lymphocyte (CTL) response. Talquetamab is approved by the U.S. Food and Drug Administration (FDA) for patients with relapsed/refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody. MW: 144.6 KD.

Description

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	2226212-40-2
Source	CHO
Storage (From the date of receipt)	-80℃

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

* Name Please enter your name.

* Email Please enter your email. Please enter a valid email address.

Phone

* Comments: Please write something to us.